Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quantum Biopharma ( (TSE:QNTM) ) has provided an update.
Quantum BioPharma reported audited financial and operational results for the fourth quarter and year ended December 31, 2025, on March 27, 2026, showing a strengthened balance sheet with $11.3 million in cash and digital assets, no going-concern warning, reduced operating expenses, and a roughly 50% cut in payables, providing a cash runway for basic operations through at least January 2028. The company also highlighted improved capital markets access, expiry of hedge fund warrants, completion of an October 27, 2025 special dividend of contingent value rights, and the resignation of director Terry Lynch effective March 27, 2026.
Operationally, Quantum advanced its MS program as Phase 1 toxicity studies of oral Lucid-MS showed no significant side effects, stability studies were completed, Phase 2 trial planning progressed with an IND filing targeted for the first half of 2026, and a first MS patient underwent PET imaging in a joint study with Massachusetts General Hospital. In its alcohol health portfolio, a peer-reviewed journal published positive clinical trial results for unbuzzd demonstrating accelerated blood alcohol reduction and improved hangover symptoms, while Health Canada granted a product license for Qlarity in Canada and Unbuzzd Wellness moved toward a potential IPO supported by a Regulation D 506(c) financing, which management expects could provide non-dilutive monetization of Quantum’s stake; the company also noted its ongoing U.S. lawsuit against CIBC and RBC over alleged stock market manipulation and is awaiting a court ruling on the banks’ motion to dismiss.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a Toronto-based biopharmaceutical company focused on innovative assets for neurodegenerative and metabolic disorders and alcohol misuse, with drug candidates at various development stages. Its pipeline includes the oral multiple sclerosis (MS) candidate Lucid-21-302 (Lucid-MS) and consumer-facing products such as the alcohol-related supplement unbuzzd and the Canadian-licensed natural health product Qlarity.
Average Trading Volume: 12,051
Technical Sentiment Signal: Sell
Current Market Cap: C$22.11M
For detailed information about QNTM stock, go to TipRanks’ Stock Analysis page.